Use of cannabis among 139 cluster headache sufferers

Leroux, Elizabeth; Taifas, Irina; Valade, Dominique; Donnet, Anne; Chagnon, Miguel; Ducros, Anne

doi:10.1177/0333102412468669

Cited by 29 publications

(32 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four studies were from Canada (Clark et al, 2004; Furler et al, 2004; Storr et al, 2014; Ware et al, 2003) and one study each was from Spain (Martínez-Rodríguez et al, 2008), the U.K. (Chong et al, 2006), France (Leroux et al, 2013), and Australia (Degenhardt et al, 2015). In Canada, the prevalence of self-medication with marijuana was modestly similar across medical conditions, except for patients with HIV.…”

Section: Resultsmentioning

confidence: 99%

“…In the U.K., Chong et al (2006) found that 30% of 254 MS patients were those who started using marijuana because of MS, which was considerably higher than those observed in Canada (Clark et al, 2004) and Spain (Martínez-Rodríguez et al, 2008). In France, Leroux et al (2013) showed that 19.4% of 139 patients with cluster headache (CH) were those who had tried marijuana to treat CH symptoms. In Australia, Degenhardt et al (2015) found that, among 1,514 individuals who have been prescribed opioids for pain, nearly 16% (95% CI: 14.0–17.6) reported ever using marijuana for pain.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review

Park

2017

Drug and Alcohol Dependence

125

View full text Add to dashboard Cite

Background The use of marijuana for medical purposes is now legal in some U.S. states and other jurisdictions, such as Canada, and Israel. Despite the widespread legalization of medical marijuana globally, there is limited information on patterns and correlates of medical marijuana use (MMU). We conducted a literature review to assess prevalence, reasons, perceived effects, and correlates of MMU among adolescents and adults. Methods We searched peer-reviewed articles in English between January 1996 and August 2016 from several databases (PubMed, Google Scholar, Embase, CINAHL, and PsycINFO) using different combinations of keywords. Results A total of 25 articles met the inclusion criteria. In the U.S., national survey estimates of prescribed MMU was 1.1% among 12th graders and 17% among adults who reported past-year marijuana use. The reported prevalence of prescribed MMU ranged from <1.7% in Israeli cancer patients to 17.4% in American health care patients. The reported prevalence of self-medication with marijuana ranged from 15% in Canadian patients with chronic pain to 30% in British patients with multiple sclerosis. Pain was the most frequently endorsed reason for use. MMU appeared to provide symptom relief for a range of pain conditions, sleep disturbance, and anxiety symptoms, but it did not appear to provide sufficient relief of cluster headache symptoms. Non-medical marijuana use was a common factor associated with MMU across studies. Conclusion Either MMU or self-medication with marijuana was common, mainly due to pain management. Additional research is needed to evaluate temporal and causal associations of non-medical marijuana use with MMU.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review

Park

2017

Drug and Alcohol Dependence

125

View full text Add to dashboard Cite

show abstract

“…For example, acute cluster attacks can be aborted with dronabinol, a synthetic THC, and within 5 min of inhalation of marijuana [28,29]. By contrast, in a survey of cluster headache patients who used cannabis, a significant portion of patients reported worsening, requiring reduced use during the active cluster headache periods [30].…”

Section: Human Datamentioning

confidence: 99%

Medical marijuana in neurology

Benbadis

Sanchez‐Ramos

Bozorg

et al. 2014

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Constituents of the Cannabis plant, cannabinoids, may be of therapeutic value in neurologic diseases. The most abundant cannabinoids are Δ(9)-tetrahydrocannabinol, which possesses psychoactive properties, and cannabidiol, which has no intrinsic psychoactive effects, but exhibits neuroprotective properties in preclinical studies. A small number of high-quality clinical trials support the safety and efficacy of cannabinoids for treatment of spasticity of multiple sclerosis, pain refractory to opioids, glaucoma, nausea and vomiting. Lower level clinical evidence indicates that cannabinoids may be useful for dystonia, tics, tremors, epilepsy, migraine and weight loss. Data are also limited in regards to adverse events and safety. Common nonspecific adverse events are similar to those of other CNS 'depressants' and include weakness, mood changes and dizziness. Cannabinoids can have cardiovascular adverse events and, when smoked chronically, may affect pulmonary function. Fatalities are rare even with recreational use. There is a concern about psychological dependence, but physical dependence is less well documented. Cannabis preparations may presently offer an option for compassionate use in severe neurologic diseases, but at this point, only when standard-of-care therapy is ineffective. As more high-quality clinical data are gathered, the therapeutic application of cannabinoids will likely expand.

show abstract

“…Récemment, une consommation régulière ou occasionnelle de drogues illicites, comme le cannabis et la cocaïne, a également été décrite comme plus importante chez les hommes souffrant d'AVF (grade C) [15]. Des données similaires ont été rapportées en France concernant le cannabis (grade C) [16].…”

Section: Facteurs De Risqueunclassified